STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 1, January-March 2021
SPECIAL ARTICLES
PEMBROLIZUMAB-AXITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA
MUÑOZ CID CARMEN LUCIA, SÁNCHEZ RUIZ ANDRÉS, CLARAMUNT GARCIA RAQUEL


The combination pembrolizumab-axitinib has recently been approved for first line treatment of advanced renal-cell carcinoma in adults. According to the pivotal KEYNOTE-426 trial, pembrolizumab-axitinib administered in previously untreated patients with this condition has obtained better efficacy results than sunitinib, with progression-free survival and overall survival being the main variables of the study. The pembrolizumab-axitinib combination has a more toxic safety profile than the alternatives sunitinib and nivolumab + ipilimumab, since the administration is up to progression. Among them, some of the most frequent are hypertension, diarrhea or palmar-plantar erythrodysesthesia. Therefore, the pembrolizumab-axitinib combination has clinical benefit, but with a very high cost, so that to get closer to reasonable levels of cost-effectiveness, a reduction in price would be appropriate.

AXITINIB – CANCER – EFFICACY – PEMBROLIZUMAB – RENAL – SAFETY



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25